Novus Therapeutics, Inc. (NVUS) financial statements (2021 and earlier)

Company profile

Business Address 19900 MACARTHUR BLVD.
IRVINE, CA 92612
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments114913172324105
Cash and cash equivalents114913172324105
Restricted cash and investments   00  
Receivables00     
Prepaid expense1112   
Other current assets0010   
Other undisclosed current assets00  6432
Total current assets:1161014193067108
Noncurrent Assets
Operating lease, right-of-use asset00
Property, plant and equipment 000000
Intangible assets, net (including goodwill)49 22   
Goodwill49 22   
Restricted cash and investments    000
Other noncurrent assets011  0 
Other undisclosed noncurrent assets32      
Total noncurrent assets:82132010
TOTAL ASSETS:1971117213068108
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2121365
Accounts payable1010011
Accrued liabilities0000253
Employee-related liabilities0010  1
Debt 0     
Postemployment benefits liability   1   
Other undisclosed current liabilities10    (1)
Total current liabilities:2121364
Noncurrent Liabilities
Long-term debt and lease obligation 0     
Operating lease, liability 0
Liabilities, other than long-term debt4    0 
Deferred income tax liabilities4 
Other liabilities     0 
Other undisclosed noncurrent liabilities    0  
Total noncurrent liabilities:40  00 
Other undisclosed liabilities  10   
Total liabilities:7131364
Stockholders' equity
Stockholders' equity attributable to parent191914192762104
Common stock0000000
Additional paid in capital271675647196193190
Accumulated other comprehensive loss    (0)(0) 
Accumulated deficit(80)(58)(42)(28)(169)(131)(86)
Total stockholders' equity:191914192762104
TOTAL LIABILITIES AND EQUITY:1971117213068108

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Operating expenses(18)(16)(14)(13)(38)(45)(23)
Operating loss:(18)(16)(14)(13)(38)(45)(23)
Nonoperating income (expense)00(0)0  0
Other nonoperating income (expense)00(0)0   
Other undisclosed loss from continuing operations before equity method investments, income taxes(5)      
Loss from continuing operations before income taxes:(23)(16)(14)(13)(38)(45)(23)
Income tax benefit0      
Net loss:(23)(16)(14)(13)(38)(45)(23)
Other undisclosed net income attributable to parent    00 
Net loss available to common stockholders, diluted:(23)(16)(14)(13)(38)(45)(23)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(23)(16)(14)(13)(38)(45)(23)
Comprehensive loss:(23)(16)(14)(13)(38)(45)(23)
Other undisclosed comprehensive income, net of tax, attributable to parent    00 
Comprehensive loss, net of tax, attributable to parent:(23)(16)(14)(13)(38)(45)(23)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: